Abstract:Background T2T is routine in RA, but no comparable standard has been defined for SLE. In 2015, the definition of Lupus Low Disease Activity State (LLDAS) was generated by Asia-Pacific Lupus Collaboration, and the preliminary validation demonstrated its attainment to be associated with improved outcomes in SLE. A SLEDAI-2K score lower than 4 is the main criteria for LLDAS. SSDM is an interactive mobile disease management application, including application systems for both the doctors and patients. The patients can perform self-assessment, including SLEDAI and medical records entry through the mobile application. The data is synchronized to the SSDM of authorized rheumatologists and stored in cloud database. Objectives To evaluate the patterns of T2T and related influential factors among SLE patients after applying SSDM in real world. Methods Patients were trained to master SSDM by rheumatologists in clinics. The first assessment for SLEDAI was performed as the baseline. Patients were required to perform repeated assessments after leaving the clinics. Results From July 2015 to Jan 2019, 1,090 SLE patients from 88 hospitals were followed up for more than 12 months through SSDM, and the results were summarized in Table 1. The ratio of T2T achievers was 52.84% (576/1,090) at the baseline and improved significantly to 68.35% (745/1,090) after a 12-month follow-up, p<0.01. Among T2T achievers at the baseline, 77.08% (444/576) maintained T2T, and 22.92% (132/576) relapsed. Of patients who didn’ t achieve T2Tat baseline, 58.56% (301/514) of the them achieve T2T after 12-month follow-up. The impact of the times of self-assessment for SLEDAI on T2T has been analyzed. The more frequent of the self-assessments being conducted by patients, the higher improvement of T2T rate will be. We performed linear regression analysis of variables in statistics and parameter estimation by least square method. The improvement of T2T rate(y) was positively correlated with times of self-assessment for SLEDAI(x) independently. The regression equation as “y = 0.0324x + 0.0226 R2 = 0.7717”, p<0.01. (Figure 1) Conclusion After proactive disease management via SSDM, the rate of T2T in SLE patients increased significantly. Patients with SLEDAI-2K≤4 score at baseline had a significantly higher retention rate. The patients who performed more self-assessments through SSDM had lower probability of relapse and higher rate of T2T maintaining and achievement. SSDM is a valuable tool for long term SLE follow-up through empowering patients.Table1: Baseline\Last follow-up Number % SLEDAI≤4 % SLEDAI≥5 % SLEDAI≤4 576 52.84% 444 77.08% 132 22.92% SLEDAI≥5 514 47.16% 301 58.56% 213 41.44% Total 1090 100% 745 68.35% 345 31.65%Figure 1 Disclosure of Interests None declared

Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus

Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity

Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study

Evaluation of Systemic Lupus Erythematosus Activity: an Update

[Assessment tools for systemic lupus erythematosus]

Patient-reported outcomes and healthcare resource utilization in systemic lupus erythematosus: impact of disease activity

Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes

Association of disease activity with depression and anxiety in systemic lupus erythematosus: a comparison of SLEDAI-2K and SLE-DAS

The Comparison of Two Systemic Lupus Erythematosus Scoring Systems for Assessing Lupus Nephritis Activity

OP0250 INFLUENTIAL FACTORS IN PROMOTING TREAT-TO-TARGET FOR SYSTEMIC LUPUS ERYTHEMATOSUS VIA EMPOWERING PATIENTS: A COHORT STUDY FROM CHINA BY SMART SYSTEM OF DISEASE MANAGEMENT (SSDM)

Comparison of Five Activity Criteria of Systemic Lupus Erythematosus

More Evidence on the Validity of the Measurement Properties of PROMIS Computerized Adaptive Tests in Systemic Lupus Erythematosus

Predicting systemic lupus erithematosus disease activity index 2000 (Sledai 2k) score after pulse dose metyl prednisolone in severe systemic lupus erithematosus

A Correlation Study on the Routine Parameters and Disease Activity of Systemic Lupus Erythematosus

Comparative Assessment of Different Health Utility Measures in Systemic Lupus Erythematosus

A potential biomarker of disease activity in systemic lupus erythematosus, systemic immune-inflammation index

Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale

Factors affecting discrepancies in disease activity evaluation between patients and physicians in systemic lupus erythematosus-The importance of symptoms such as fatigue

Association of systemic lupus erythematosus disease activity index score with clinical and laboratory parameters in pediatric onset systemic lupus erythematosus

Lupus Low Disease Activity State and organ damage in relation to quality of life in systemic lupus erythematosus: a cohort study with up to 11 years of follow-up

E058 Disease activity measurement in rheumatoid arthritis - simpler in not always better!